Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $28.6652W HIGH $126.38
Volume
1.87 M
Value Traded
143.19 M
Short % Float
8.92%
Days to Cover
3.6
-22.28%Week
-24.65%1 Month
-4.38%3 Month
+88.5%6 Month
+176.37%5 Year
+391.59%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.42 B
EPS (TTM)
0.51
P/E Ratio
170.67
Ent. Value
8.87 B
Total Shares
108.05 M
Float Shares
95.77 M
Insiders
11.40%
Institutions
76.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CORT Catalyst Timeline
Dated clinical, regulatory and corporate events for Corcept Therapeutics Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Corcept Therapeutics Incorporated
827Total events
23Upcoming
202Tier-1 (high impact)
2007 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲PublicationPresentation
ADA/EASD 2026 Consensus Report on Management of Type 2 Diabetes published, recommending hypercortisolism screening
hypercortisolism in difficult-to-control type 2 diabetessource ↗
▲CHMP Positive OpinionRelacorilantApprovedEx-US Regulatory
CHMP positive opinion recommending EU approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer
platinum-resistant ovarian cancersource ↗
▲CHMP Positive OpinionLifyorliApprovedEx-US Regulatory
CHMP recommends EU marketing authorization for Lifyorli (relacorilant)
●Poster PresentationPresentation
Poster presented at ASPC 2026 Congress on CVD Prevention
Hypercortisolism in resistant hypertension and cardiovascular diseasesource ↗
●NDA SubmissionRelacorilantApprovedRegulatory Filing
Resubmission of NDA for Relacorilant in Cushing's Syndrome
Cushing's Syndromesource ↗
◆Oral PresentationKorlymApprovedPresentation
Presentation of new data at ADA on Korlym in patients receiving a GLP-1 with difficult-to-control type 2 diabetes and hypercortisolism
difficult-to-control type 2 diabetes and hypercortisolismsource ↗
●NDA SubmissionRelacorilantApprovedRegulatory Filing
NDA for relacorilant in Cushing's syndrome resubmitted
Cushing's syndromesource ↗
▲Oral PresentationRelacorilantApprovedPresentation
CATALYST and MOMENTUM new data presented at ADA 86th Scientific Sessions
hypercortisolismsource ↗
▲Oral PresentationLifyorliApprovedPresentation
Oral presentation of overall survival data from ROSELLA trial at ASCO 2026
platinum-resistant ovarian cancersource ↗
◆NDA SubmissionRelacorilantApprovedRegulatory Filing
Resubmission of NDA for relacorilant
Cushing's syndromesource ↗
▲Full ResultsDazucorilantClinical Data
Two-year overall survival data from Phase 2 DAZALS study
amyotrophic lateral sclerosissource ↗
▼Primary Endpoint MissedDazucorilantClinical Data
DAZALS did not meet primary endpoint (ALSFRS-R at 24 weeks)
amyotrophic lateral sclerosissource ↗
▲Full ResultsLifyorliApprovedClinical Data
Presentazione dei dati finali di sopravvivenza globale dello studio di fase III ROSELLA su Lifyorli (relacorilant) in combinazione con nab-paclitaxel
tumore ovarico resistente al platinosource ↗
◆Oral PresentationLifyorliApprovedPresentation
Presentación oral en el Congreso Anual 2026 de la SGO
cáncer de ovario resistente al platinosource ↗
◆PublicationLifyorliApprovedPresentation
Publicación simultánea en The Lancet
cáncer de ovario resistente al platinosource ↗
▲Late-BreakerLifyorliApprovedPresentation
Late-breaker presentation of ROSELLA study results at SGO 2026
platinum-resistant ovarian cancersource ↗
▲Primary Endpoint MetLifyorliApprovedClinical Data
ROSELLA met both primary endpoints: overall survival and progression-free survival
platinum-resistant ovarian cancersource ↗
●PublicationrélacorilantPresentation
Publication simultanée dans The Lancet des résultats de l'essai ROSELLA
cancer de l'ovaire résistant au platinesource ↗
▲FDA ApprovalLifyorliApprovedFDA Decision
FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer
platinum-resistant ovarian cancersource ↗
◆Oral PresentationLifyorliApprovedPresentation
Complete ROSELLA results to be presented at SGO meeting in April
platinum-resistant ovarian cancersource ↗
▲Full ResultsRelacorilantApprovedClinical Data
ROSELLA complete results presented at SGO and published in The Lancet
platinum-resistant ovarian cancersource ↗
▲PublicationRelacorilantApprovedPresentation
ROSELLA results published in The Lancet
platinum-resistant ovarian cancersource ↗
▲Enrollment CompleteRelacorilantApprovedTrial
BELLA Part A enrollment completed
platinum-resistant ovarian cancersource ↗
●EU MAA SubmissionRelacorilantApprovedEx-US Regulatory
MAA submitted to EMA for relacorilant plus nab-paclitaxel
platinum-resistant ovarian cancersource ↗
●NDA SubmissionRelacorilantApprovedRegulatory Filing
NDA for relacorilant in Cushing's syndrome under FDA engagement
Cushing's syndromesource ↗
◆Late-BreakerPresentation
Late-breaking data from MOMENTUM trial presented at ACC 2026
resistant hypertensionsource ↗
◆Oral PresentationPresentation
Featured Clinical Research presentation at ACC 2026
resistant hypertensionsource ↗
▲FDA ApprovalLifyorliApprovedFDA Decision
FDA approval of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer
cáncer de ovario resistente al platinosource ↗
▲FDA ApprovalLifyorliApprovedFDA Decision
FDA approval of Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer
platinum-resistant ovarian cancersource ↗
▲Primary Endpoint MetLifyorliApprovedClinical Data
ROSELLA met dual primary endpoints of PFS and OS
platinum-resistant ovarian cancersource ↗
▼Short Report ActivistCorporate
Securities class action lawsuit filed against Corcept Therapeutics
▲FDA ApprovalLifyorliApprovedFDA Decision
FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer
platinum-resistant ovarian cancersource ↗
◆Oral PresentationRelacorilantApprovedPresentation
MOMENTUM results presented at ACC
hypercortisolism in resistant hypertensionsource ↗
◆Oral PresentationPresentation
MOMENTUM trial results oral presentation at ACC meeting
resistant hypertensionsource ↗
Past FDA Catalysts and PDUFA Decisions
How CORT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-29 | Lifyorli™ (relacorilant) plus nab-paclitaxel | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
6
Drugs Scored
rNPV / MCap
Top Drug
Top 7%
Small Cap(rank 47 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Hypercortisolism Products | |||
| Lifyorli |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dazucorilant Small moleculeNCT05407324 | Amyotrophic Lateral Sclerosis | Phase 2 | ACTIVE NOT_RECRUITING | 279 | Nov 1, 2027 | ||||||
| Relacorilant Small moleculeMarketedNCT05257408 | Ovarian Neoplasm | Phase 3 | ACTIVE NOT_RECRUITING | 381 | Dec 1, 2026 | ||||||
| Relacorilant Small moleculeMarketedNCT06906341 | Ovarian Cancer | Phase 2 | RECRUITING | 270 | Dec 1, 2026 | ||||||
| Relacorilant Small moleculeMarketedNCT07259317 | Adenocarcinoma | Phase 2 | RECRUITING | 80 | Sep 1, 2027 | ||||||
| Relacorilant Small moleculeNCT03604198 | Cushing Syndrome | NDA/BLA | ACTIVE NOT_RECRUITING | 307 | Dec 1, 2026 | ||||||
| Nenocorilant Small moleculeNCT07276373 | Neoplasms | Phase 1 | RECRUITING | 50 | Jan 1, 2027 | ||||||
| Miricorilant Small moleculeCompletedNCT06947304 | Nonalcoholic Steatohepatitis (NASH) | Phase 2 | COMPLETED | 268 | Sep 15, 2026 | ||||||
| Miricorilant Small moleculeCompletedNCT05712265 | Antipsychotic Induced Weight Gain | Phase 2 | COMPLETED | 97 | Feb 23, 2023 | ||||||
| Miricorlilant Small moleculeCompletedNCT04524403 | Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | COMPLETED | 150 | Aug 25, 2022 | ||||||
| Miricorilant Small moleculeCompletedNCT05553470 | Non-alcoholic Steatohepatitis (NASH) | Phase 1 | COMPLETED | 19 | Sep 13, 2024 | ||||||
| Miricorilant Treatment A Small moleculeCompletedNCT07240116 | Undisclosed | Phase 1 | COMPLETED | 18 | Mar 3, 2026 | ||||||
| CORT118335 Small moleculeCompletedNCT03877562 | Antipsychotic-induced Weight Gain | Phase 1 | COMPLETED | 96 | Mar 25, 2020 | ||||||
| Dazucorilant Small moleculeCompletedNCT06928779 | Hepatic Impairment | Phase 1 | COMPLETED | 19 | Dec 9, 2024 | ||||||
| CORT113176 Small moleculeCompletedNCT04994743 | Undisclosed | Phase 1 | COMPLETED | 22 | Sep 30, 2021 | ||||||
| Relacorilant Small moleculeMarketedNCT04308590 | Hypercortisolism | Phase 3 | COMPLETED | 137 | Sep 19, 2024 | ||||||
| Relacorilant Small moleculeMarketedNCT03776812 | Recurrent Ovarian Cancer | Phase 2 | COMPLETED | 178 | Jul 12, 2023 | ||||||
| Relacorilant Small moleculeMarketedNCT06094725 | Hepatic Impairment | Phase 1 | COMPLETED | 30 | Dec 14, 2020 | ||||||
| Relacorilant Small moleculeMarketedNCT02762981 | Solid Tumors | Phase 1 | COMPLETED | 85 | Sep 12, 2020 | ||||||
| Relacorilant Small moleculeMarketedNCT04373265 | Adrenocortical Carcinoma | Phase 1 | COMPLETED | 15 | Jan 12, 2024 | ||||||
| Relacorilant Small moleculeMarketedNCT03674814 | Prostate Cancer | Phase 1 | COMPLETED | 42 | Jun 10, 2024 | ||||||
| CORT125134 Small moleculeCompletedNCT02804750 | Cushing's Syndrome | NDA/BLA | COMPLETED | 35 | Sep 1, 2018 | ||||||
| CORT125236 Small moleculeCompletedNCT05003713 | Undisclosed | Phase 1 | COMPLETED | 82 | Feb 3, 2023 | ||||||
| CORT125281 Small moleculeCompletedNCT03335956 | Undisclosed | Phase 1 | COMPLETED | 48 | Jun 25, 2018 | ||||||
| CORT125329 lipid formulation Small moleculeCompletedNCT04672512 | Undisclosed | Phase 1 | COMPLETED | 115 | Jan 17, 2022 | ||||||
| Mifepristone Small moleculeMarketedNCT00936741 | Cushing's Syndrome | Phase 3 | COMPLETED | 80 | Sep 1, 2012 |
Clinical Trial Results
Readouts, endpoints and source filings for every CORT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Lifyorli | platinum-resistant ovarian cancer | Phase 2 | 2026-10-26 | median progression free survival: 7.2 months; objective response rate: 59%; median progression free survival bevacizumab naive: 8.1 months; objective response rate bevacizumab naive: 66%; overall survival 6 months: 91%Read More | Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WILSON JAMES NDirector | Sell | -6,654 1,057,889 held | $114.48 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CORT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 5.9 % (90.3 %) | 130.43 M | 1.50 M |
CORT Institutional Ownership Trends
CORT Short Interest
Shares sold short, counted twice a month.
8.92%
Short % of Float
of tradable shares sold short
8.5M
Shares Sold Short
-8.7% vs prior count
3.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CORT ranks across every disease it competes in
Competitive Position is a premium feature
See how CORT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCORT News
CORT▲ +0.2%today
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics announced positive results from its Phase 2 BELLA trial, where Lifyorli combined with nab-paclitaxel and bevacizumab showed significant improvements in progression-free survival and objective response rate in patients with platinum-resistant ovarian cancer. The median progression-free survival was 7.2 months, with 59% achieving an objective response. Results were particularly favorable for patients who had not previously received bevacizumab.
Read more →CORT2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
The 2026 ADA/EASD consensus report recommends screening for hypercortisolism in adults with difficult-to-control type 2 diabetes. This recommendation is based on Corcept's CATALYST study, which showed that cortisol-directed therapy with mifepristone significantly reduced HbA1c levels. The report highlights the importance of identifying treatable causes of hyperglycemia in these patients.
Read more →CORTCorcept Announces Planned Leadership Transition
Corcept Therapeutics has announced the retirement of Sean Maduck, the President of its Endocrinology division. Justin Gunn will take over his responsibilities starting in October. This leadership change is part of the company's ongoing strategy to enhance its focus on developing treatments for various severe disorders.
Read more →CORTCorcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Corcept Therapeutics announced that the CHMP has recommended the approval of relacorilant for marketing authorization in the European Union. This recommendation is a significant step towards making the drug available to patients in Europe. The approval could enhance Corcept's market presence and support its mission to treat severe disorders.
Read more →CORTPrevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease
The presentation titled 'Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease' was delivered by Dr. Pam R. Taub at the American Society for Preventive Cardiology Congress on July 31, 2026. This research highlights the prevalence of hypercortisolism in patients facing resistant hypertension and cardiovascular issues, suggesting important clinical implications.
Read more →CORT▲ +27.3%on this newsshared move
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics reported strong financial results for the second quarter of 2026, highlighting the success of its oncology and Cushing's syndrome segments. The company continues to focus on developing medications that modulate cortisol effects for various severe disorders. This positive performance reflects the company's growth and market presence.
Read more →CORT▲ +6.4%on this news
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics has announced the date for its second quarter financial results report, set for July 29, 2026. The company will provide a corporate update during this time and host a conference call at 5:00 p.m. Eastern Time. Participants are required to register in advance to receive access details.
Read more →CORTPrevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study
The MOMENTUM study, presented at the 10th Annual Heart in Diabetes CME Conference, explores the prevalence of endogenous hypercortisolism in individuals with resistant hypertension, stratified by kidney function. The findings aim to enhance understanding of this condition and its implications for treatment. The presentation was made by Dr. Ralph A. DeFronzo.
Read more →CORTEfficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)
The Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10) presented findings on the efficacy and safety of Relacorilant combined with Nab-paclitaxel in treating platinum-resistant ovarian cancer in patients aged 65 and older. The results were shared at the European Society for Medical Oncology Gynaecological Cancers Annual Congress. The study's focus on older patients addresses a significant gap in treatment options.
Read more →CORTReal-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)
The COMPASS 2.0 study evaluates the comparative effectiveness of nab-paclitaxel versus standard chemotherapy in patients with platinum-resistant ovarian cancer. Presented by Dr. Mark S. Shahin at the European Society for Medical Oncology Gynaecological Cancers Annual Congress, the findings contribute valuable insights into treatment options for this challenging patient population.
Read more →CORTCorcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, intended for the treatment of Cushing's syndrome. This resubmission follows previous interactions with the FDA. The company aims to address the needs of patients suffering from this condition with its investigational therapy.
Read more →CORTEndogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies
The article discusses the presentation of results from two large prospective studies on endogenous hypercortisolism in patients with resistant hypertension and difficult-to-control type 2 diabetes. The findings were presented by Dr. Ralph DeFronzo at the Endocrine Society Annual Meeting in Chicago. This research highlights important health implications for managing these conditions.
Read more →CORTCharacterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol 1.8 μg/dL: Results From the MOMENTUM Study
The MOMENTUM Study results were presented at the Endocrine Society Annual Meeting, highlighting the characterization of individuals with resistant hypertension and their cortisol levels post-dexamethasone suppression test. The findings may provide valuable insights into managing this condition. The study emphasizes the importance of cortisol measurements in understanding hypertension resistance.
Read more →CORTHigh Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study
The MOMENTUM study presented by Dr. Guillermo Umpierrez at the American Diabetes Association Scientific Sessions revealed a high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension. This research adds important knowledge to the understanding of the interplay between these conditions. The findings were shared at a prominent scientific event in New Orleans.
Read more →CORTEffects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs
The presentation titled 'Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs' was delivered by Dr. Lance A. Sloan at the American Diabetes Association Scientific Sessions on June 6, 2026. It discusses the impact of mifepristone on patients struggling with type 2 diabetes and hypercortisolism, particularly in relation to GLP-1 receptor agonists.
Read more →CORTCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Corcept has presented new data at the ADA conference regarding the outcomes of patients with difficult-to-control Type 2 diabetes and hypercortisolism treated with Korlym®. The findings suggest improvements in patient outcomes when Korlym® is used alongside GLP-1 receptor agonists. Further details on the data and implications for treatment were highlighted during the presentation.
Read more →CORTSYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies
The SYNERGY study investigates the efficacy of nenocorilant combined with nivolumab in patients with advanced solid tumors. Presented by Dr. Omid Hamid at the American Society of Clinical Oncology Annual Meeting, this Phase 1b/2 trial aims to provide insights into this innovative treatment approach. The findings may contribute to new therapeutic strategies in oncology.
Read more →CORTTRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma
The TRIDENT study investigates the efficacy of relacorilant combined with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma. Presented at the American Society of Clinical Oncology Annual Meeting, the study aims to provide insights into new treatment options for this challenging cancer type.
Read more →CORTOverall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer
The Phase 3 ROSELLA trial results were presented at the American Society of Clinical Oncology Annual Meeting, highlighting the overall survival subgroup analyses for patients with platinum-resistant ovarian cancer. The study compares the efficacy of relacorilant plus nab-paclitaxel against nab-paclitaxel monotherapy, focusing on patients with prior taxane use. The findings suggest potential benefits of the combination therapy.
Read more →CORTCorcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Corcept has presented new data at ASCO 2026 regarding Lifyorli™ and its overall survival benefits for patients with platinum-resistant ovarian cancer. The data includes insights across all patient subgroups, particularly those with recent taxane exposure. This presentation highlights the ongoing research and potential impact of Lifyorli™ in treating this challenging cancer type.
Read more →About Corcept Therapeutics Incorporated
Headquarters101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
BIOPHARMAWATCH ELITE PLUS
Trade the next CORT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime